Literature DB >> 20619428

Systemic inflammation and the metabolic syndrome among middle-aged community volunteers.

Anna L Marsland1, Jeanne M McCaffery, Matthew F Muldoon, Stephen B Manuck.   

Abstract

The metabolic syndrome is conceptualized as a clustering of risk factors--including insulin resistance, dyslipidemia, central adiposity, and elevated blood pressure (BP)--that increase the risk for cardiovascular disease and type 2 diabetes mellitus. Recent evidence suggests that markers of systemic inflammation may be included in the definition of the syndrome and play some role in its pathogenesis. In this study, we use a statistical modeling technique, confirmatory factor analysis, to evaluate relationships of systemic inflammation, as measured by plasma concentrations of C-reactive protein and interleukin-6, with the component factors of the metabolic syndrome (insulin resistance, dyslipidemia, central adiposity, and elevated BP) and to examine whether inflammation is a potential common pathway linking established components to the full syndrome. Subjects were 645 community volunteers aged 30 to 54 years (48% male, 82% European American, 18% African American). Consistent with existing literature, structural equation modeling adjusting for age, sex, and race confirmed a higher-order common factor underlying the covariation of insulin resistance, dyslipidemia, adiposity, and BP. Inflammation was positively associated with this common factor, accounting for 54% of its variance and partially mediating statistical aggregation of the component factors comprising the metabolic syndrome. These results were particularly strong for adiposity, raising the possibility that inflammatory processes stimulated by intraabdominal adipose tissue contribute to the development of the metabolic syndrome. The inclusion of inflammatory markers in the clinical definition of metabolic syndrome seems warranted and may improve prognostic assessment of risk of type 2 diabetes mellitus and cardiovascular disease.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20619428      PMCID: PMC2955187          DOI: 10.1016/j.metabol.2010.05.015

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  42 in total

1.  Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.

Authors:  Katherine Esposito; Alessandro Pontillo; Carmen Di Palo; Giovanni Giugliano; Mariangela Masella; Raffaele Marfella; Dario Giugliano
Journal:  JAMA       Date:  2003-04-09       Impact factor: 56.272

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

3.  Is inflammation a causal chain between low socioeconomic status and type 2 diabetes? Results from the KORA Survey 2000.

Authors:  Wolfgang Rathmann; Burkhard Haastert; Guido Giani; Wolfgang Koenig; Armin Imhof; Christian Herder; Rolf Holle; Andreas Mielck
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

4.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; G Howard; L Mykkänen; R P Tracy; S M Haffner
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

5.  Impact of weight loss on the metabolic syndrome.

Authors:  S Phelan; T A Wadden; R I Berkowitz; D B Sarwer; L G Womble; R K Cato; R Rothman
Journal:  Int J Obes (Lond)       Date:  2007-03-13       Impact factor: 5.095

6.  Associations between dietary fiber and inflammation, hepatic function, and risk of type 2 diabetes in older men: potential mechanisms for the benefits of fiber on diabetes risk.

Authors:  S Goya Wannamethee; Peter H Whincup; Mary C Thomas; Naveed Sattar
Journal:  Diabetes Care       Date:  2009-07-23       Impact factor: 17.152

7.  Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity.

Authors:  Anthony J G Hanley; Andreas Festa; Ralph B D'Agostino; Lynne E Wagenknecht; Peter J Savage; Russell P Tracy; Mohammed F Saad; Steven M Haffner
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

8.  Socioeconomic position and the metabolic syndrome in early, middle, and late life: evidence from NHANES 1999-2002.

Authors:  Eric B Loucks; Kristjan T Magnusson; Stephen Cook; David H Rehkopf; Earl S Ford; Lisa F Berkman
Journal:  Ann Epidemiol       Date:  2007-08-13       Impact factor: 3.797

9.  Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators.

Authors:  M I Schmidt; R L Watson; B B Duncan; P Metcalf; F L Brancati; A R Sharrett; C E Davis; G Heiss
Journal:  Metabolism       Date:  1996-06       Impact factor: 8.694

10.  Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.

Authors:  Nehal N Mehta; Fiona C McGillicuddy; Paul D Anderson; Christine C Hinkle; Rachana Shah; Leticia Pruscino; Jennifer Tabita-Martinez; Kim F Sellers; Michael R Rickels; Muredach P Reilly
Journal:  Diabetes       Date:  2009-09-30       Impact factor: 9.461

View more
  42 in total

1.  Replication and meta-analysis of the gene-environment interaction between body mass index and the interleukin-6 promoter polymorphism with higher insulin resistance.

Authors:  Patricia C Underwood; Bindu Chamarthi; Jonathan S Williams; Bei Sun; Anand Vaidya; Benjamin A Raby; Jessica Lasky-Su; Paul N Hopkins; Gail K Adler; Gordon H Williams
Journal:  Metabolism       Date:  2011-11-08       Impact factor: 8.694

Review 2.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  Inflammation Partially Mediates the Association of Multimorbidity and Functional Limitations in a National Sample of Middle-Aged and Older Adults: The MIDUS Study.

Authors:  Elliot M Friedman; Sharon L Christ; Daniel K Mroczek
Journal:  J Aging Health       Date:  2015-02-02

4.  Gender Differences in the Pattern of Socio-Demographics Relevant to Metabolic Syndrome Among Kenyan Adults with Central Obesity at a Mission Hospital in Nairobi, Kenya.

Authors:  Okubatsion Tekeste Okube; Samuel T Kimani; Waithira Mirie
Journal:  High Blood Press Cardiovasc Prev       Date:  2020-01-25

Review 5.  Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Authors:  Cecilia J Hillard
Journal:  Neuropsychopharmacology       Date:  2017-06-27       Impact factor: 7.853

6.  Low-energy cranberry juice decreases lipid oxidation and increases plasma antioxidant capacity in women with metabolic syndrome.

Authors:  Arpita Basu; Nancy M Betts; Jennifer Ortiz; Brandi Simmons; Mingyuan Wu; Timothy J Lyons
Journal:  Nutr Res       Date:  2011-03       Impact factor: 3.315

7.  Borderline personality disorder traits associate with midlife cardiometabolic risk.

Authors:  Taylor A Barber; Whitney R Ringwald; Aidan G C Wright; Stephen B Manuck
Journal:  Personal Disord       Date:  2019-10-24

8.  Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis.

Authors:  Mark M Smits; Pier Woudstra; Kristina M Utzschneider; Jenny Tong; Fernando Gerchman; Mirjam Faulenbach; Darcy B Carr; Kathryn Aston-Mourney; Alan Chait; Robert H Knopp; James B Meigs; Edward J Boyko; Steven E Kahn
Journal:  Ann Epidemiol       Date:  2013-03-25       Impact factor: 3.797

9.  Neutrophil-to-Lymphocyte Ratio as a Marker in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy.

Authors:  Onur Polat; Güliz Fatma Yavaş; Sibel İnan; Ümit Übeyt İnan
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

10.  Modeling Multisystem Physiological Dysregulation.

Authors:  Joshua F Wiley; Tara L Gruenewald; Arun S Karlamangla; Teresa E Seeman
Journal:  Psychosom Med       Date:  2016-04       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.